{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T07:35:25Z","timestamp":1782027325063,"version":"3.54.5"},"reference-count":57,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>The plaque reduction neutralization test (PRNT) is a specific serological test used to identify and confirm arbovirus infection in diagnostic laboratories and monitor immunological protection in vaccine recipients. Wild-type (wt) viruses used in the PRNT may be difficult to grow and plaque titrate, such as the dengue viruses (DENV), and\/or may require biosafety level 3 (BSL3) containment, such as West Nile virus (WNV), St. Louis encephalitis virus (SLEV), and Japanese encephalitis virus (JEV). These requirements preclude their use in diagnostic laboratories with only BSL2 capacity. In addition, wt JEV falls under the jurisdiction of the select-agent program and can be used only in approved laboratories. The chimeric vaccine viruses ChimeriVax-WNV and -SLEV have previously been shown to elicit antibody reactivity comparable to that of parental wt WNV and SLEV. ChimeriVax viruses provide advantages for PRNT, as follows: they grow more rapidly than most wt flaviviruses, produce large plaques, require BSL2 conditions, and are not under select-agent restrictions. We evaluated the ChimeriVax-DENV serotype 1 (DENV1), -DENV2, -DENV3, -DENV4, and -JEV for use in PRNT on sera from DENV- and JEV-infected patients and from JEV vaccine recipients. Serostatus agreement was 100% between the ChimeriVax-DENV serotypes and wt prototype DENV and 97% overall with ChimeriVax-JEV compared to prototype Nakayama JEV, 92% in a subgroup of JEV vaccine recipients, and 100% in serum from encephalitis patients naturally infected with JEV. ChimeriVax-DENV and -JEV plaque phenotype and BSL2 requirements, combined with sensitive and specific reactivity, make them good substitutes for wt DENV and JEV in PRNT in public health diagnostic laboratories.<\/jats:p>","DOI":"10.1128\/cvi.00095-09","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T01:34:13Z","timestamp":1242869653000},"page":"1052-1059","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":39,"title":["Evaluation of Chimeric Japanese Encephalitis and Dengue Viruses for Use in Diagnostic Plaque Reduction Neutralization Tests"],"prefix":"10.1128","volume":"16","author":[{"given":"Barbara W.","family":"Johnson","sequence":"first","affiliation":[{"name":"Diagnostic &amp; Reference Laboratory, Arbovirus Diseases Branch, Centers for Disease Control and Prevention (CDC), Division of Vector-Borne Infectious Diseases (DVBID), 3150 Rampart Road, Fort Collins, Colorado 80521"},{"name":"Serology Diagnostics and Viral Pathogenesis Laboratory, Dengue Branch, CDC, DVBID, San Juan, Puerto Rico"},{"name":"Sanofi Pasteur, 1541 Avenue Marcel Merieux-D Est 2, 69280 Marcy l'Etoile, France"},{"name":"Kleiner Perkins Caufield &amp; Byers Pandemic &amp; Biodefense Fund, 21 Finn Road, Harvard, Massachusetts 01451"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Kosoy","sequence":"additional","affiliation":[{"name":"Diagnostic &amp; Reference Laboratory, Arbovirus Diseases Branch, Centers for Disease Control and Prevention (CDC), Division of Vector-Borne Infectious Diseases (DVBID), 3150 Rampart Road, Fort Collins, Colorado 80521"},{"name":"Serology Diagnostics and Viral Pathogenesis Laboratory, Dengue Branch, CDC, DVBID, San Juan, Puerto Rico"},{"name":"Sanofi Pasteur, 1541 Avenue Marcel Merieux-D Est 2, 69280 Marcy l'Etoile, France"},{"name":"Kleiner Perkins Caufield &amp; Byers Pandemic &amp; Biodefense Fund, 21 Finn Road, Harvard, Massachusetts 01451"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hunsperger","sequence":"additional","affiliation":[{"name":"Diagnostic &amp; Reference Laboratory, Arbovirus Diseases Branch, Centers for Disease Control and Prevention (CDC), Division of Vector-Borne Infectious Diseases (DVBID), 3150 Rampart Road, Fort Collins, Colorado 80521"},{"name":"Serology Diagnostics and Viral Pathogenesis Laboratory, Dengue Branch, CDC, DVBID, San Juan, Puerto Rico"},{"name":"Sanofi Pasteur, 1541 Avenue Marcel Merieux-D Est 2, 69280 Marcy l'Etoile, France"},{"name":"Kleiner Perkins Caufield &amp; Byers Pandemic &amp; Biodefense Fund, 21 Finn Road, Harvard, Massachusetts 01451"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Beltran","sequence":"additional","affiliation":[{"name":"Diagnostic &amp; Reference Laboratory, Arbovirus Diseases Branch, Centers for Disease Control and Prevention (CDC), Division of Vector-Borne Infectious Diseases (DVBID), 3150 Rampart Road, Fort Collins, Colorado 80521"},{"name":"Serology Diagnostics and Viral Pathogenesis Laboratory, Dengue Branch, CDC, DVBID, San Juan, Puerto Rico"},{"name":"Sanofi Pasteur, 1541 Avenue Marcel Merieux-D Est 2, 69280 Marcy l'Etoile, France"},{"name":"Kleiner Perkins Caufield &amp; Byers Pandemic &amp; Biodefense Fund, 21 Finn Road, Harvard, Massachusetts 01451"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Delorey","sequence":"additional","affiliation":[{"name":"Diagnostic &amp; Reference Laboratory, Arbovirus Diseases Branch, Centers for Disease Control and Prevention (CDC), Division of Vector-Borne Infectious Diseases (DVBID), 3150 Rampart Road, Fort Collins, Colorado 80521"},{"name":"Serology Diagnostics and Viral Pathogenesis Laboratory, Dengue Branch, CDC, DVBID, San Juan, Puerto Rico"},{"name":"Sanofi Pasteur, 1541 Avenue Marcel Merieux-D Est 2, 69280 Marcy l'Etoile, France"},{"name":"Kleiner Perkins Caufield &amp; Byers Pandemic &amp; Biodefense Fund, 21 Finn Road, Harvard, Massachusetts 01451"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad","family":"Guirakhoo","sequence":"additional","affiliation":[{"name":"Diagnostic &amp; Reference Laboratory, Arbovirus Diseases Branch, Centers for Disease Control and Prevention (CDC), Division of Vector-Borne Infectious Diseases (DVBID), 3150 Rampart Road, Fort Collins, Colorado 80521"},{"name":"Serology Diagnostics and Viral Pathogenesis Laboratory, Dengue Branch, CDC, DVBID, San Juan, Puerto Rico"},{"name":"Sanofi Pasteur, 1541 Avenue Marcel Merieux-D Est 2, 69280 Marcy l'Etoile, France"},{"name":"Kleiner Perkins Caufield &amp; Byers Pandemic &amp; Biodefense Fund, 21 Finn Road, Harvard, Massachusetts 01451"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Monath","sequence":"additional","affiliation":[{"name":"Diagnostic &amp; Reference Laboratory, Arbovirus Diseases Branch, Centers for Disease Control and Prevention (CDC), Division of Vector-Borne Infectious Diseases (DVBID), 3150 Rampart Road, Fort Collins, Colorado 80521"},{"name":"Serology Diagnostics and Viral Pathogenesis Laboratory, Dengue Branch, CDC, DVBID, San Juan, Puerto Rico"},{"name":"Sanofi Pasteur, 1541 Avenue Marcel Merieux-D Est 2, 69280 Marcy l'Etoile, France"},{"name":"Kleiner Perkins Caufield &amp; Byers Pandemic &amp; Biodefense Fund, 21 Finn Road, Harvard, Massachusetts 01451"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1348-0421.1997.tb01196.x","volume":"41","year":"1997","unstructured":"Ali, A., and A. Igarashi. 1997. Antigenic and genetic variations among Japanese encephalitis virus strains belonging to genotype 1. Microbiol. Immunol.41:241-252.","journal-title":"Microbiol. Immunol."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/BF01322530","volume":"140","year":"1995","unstructured":"Ali, A., A. Igarashi, L. R. Paneru, F. Hasebe, K. Morita, M. Takagi, W. Suwonkerd, Y. Tsuda, and Y. Wada. 1995. Characterization of two Japanese encephalitis virus strains isolated in Thailand. Arch. Virol.140:1557-1575.","journal-title":"Arch. Virol."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1471-4914(01)02048-2","volume":"7","year":"2001","unstructured":"Arroyo, J., C. A. Miller, J. Catalan, and T. P. Monath. 2001. Yellow fever vector live-virus vaccines: West Nile virus vaccine development. Trends Mol. Med.7:350-354.","journal-title":"Trends Mol. Med."},{"key":"e_1_3_2_5_2","first-page":"189","year":"1995","unstructured":"Beaty, B., C. Calisher, and R. Shope. 1995. Arboviruses, p. 189-212. In E. Lennette, D. Lennette, and E. Lennette (ed.), Diagnostic procedures for viral, rickettsial, and chlamydial infections, 7th ed. American Public Health Association, Washington, DC.","journal-title":"Diagnostic procedures for viral, rickettsial, and chlamydial infections"},{"key":"e_1_3_2_6_2","first-page":"1043","volume":"1","year":"2001","unstructured":"Burke, D., and T. P. Monath. 2001. Flaviviruses, p. 1043-1125. In D. Knipe and P. Howley (ed.), Fields virology, 4th ed., vol. 1. Lippincott Williams and Wilkins, Philadelphia, PA.","journal-title":"Fields virology"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.16.6.1034-1042.1982"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1099\/0022-1317-70-1-37","volume":"70","year":"1989","unstructured":"Calisher, C. H., N. Karabatsos, J. M. Dalrymple, R. E. Shope, J. S. Porterfield, E. G. Westaway, and W. E. Brandt. 1989. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J. Gen. Virol.70:37-43.","journal-title":"J. Gen. Virol."},{"key":"e_1_3_2_9_2","first-page":"45944","volume":"66","year":"2001","unstructured":"Centers for Disease Control and Prevention, Department of Health and Human Services. 2001. Requirements for facilities transferring or receiving select agents. Final rule. Fed. Regist.66:45944-45945.","journal-title":"Final rule. Fed. Regist."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.4.3095-3101.1999"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00842-06"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0042-6822(56)90017-4","volume":"2","year":"1956","unstructured":"Dulbecco, R., M. Vogt, and A. G. Strickland. 1956. A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus. Virology2:162-205.","journal-title":"Virology"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.biologicals.2007.07.002","volume":"36","year":"2008","unstructured":"Ferguson, M., S. Johnes, L. Li, A. Heath, and A. Barrett. 2008. Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines\u2014report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies. Biologicals36:111-116.","journal-title":"Biologicals"},{"key":"e_1_3_2_14_2","unstructured":"Statistical methods for rates and proportions 1981"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/0470058005.ch2","volume":"277","year":"2006","unstructured":"Gubler, D. J. 2006. Dengue\/dengue haemorrhagic fever: history and current status. Novartis Found. Symp.277:3-16; discussion, 16-22, 71-73, 251-253.","journal-title":"Novartis Found. Symp."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1874-5326(07)80025-1","volume":"1","year":"1998","unstructured":"Gubler, D. J. 1998. Epidemic dengue and dengue hemorrhagic fever: a global public health problem in the 21st century, p. 1-14. In W. Scheld, D. Armstrong, and J. Hughes (ed.), Emerging infections,vol. 1. ASM Press, Washington, DC.","journal-title":"Emerging infections"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0188-4409(02)00378-8","volume":"33","year":"2002","unstructured":"Gubler, D. J. 2002. The global emergence\/resurgence of arboviral diseases as public health problems. Arch. Med. Res.33:330-342.","journal-title":"Arch. Med. Res."},{"key":"e_1_3_2_18_2","first-page":"227","volume":"27","year":"1998","unstructured":"Gubler, D. J. 1998. The global pandemic of dengue\/dengue haemorrhagic fever: current status and prospects for the future. Ann. Acad. Med. Singapore27:227-234.","journal-title":"Ann. Acad. Med. Singapore"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.16.7290-7304.2001"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1006\/viro.2002.1462","volume":"298","year":"2002","unstructured":"Guirakhoo, F., K. Pugachev, J. Arroyo, C. Miller, Z. X. Zhang, R. Weltzin, K. Georgakopoulos, J. Catalan, S. Ocran, K. Draper, and T. P. Monath. 2002. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology298:146-159.","journal-title":"Virology"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1006\/viro.1999.9695","volume":"257","year":"1999","unstructured":"Guirakhoo, F., Z. X. Zhang, T. J. Chambers, S. Delagrave, J. Arroyo, A. D. Barrett, and T. P. Monath. 1999. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology257:363-372.","journal-title":"Virology"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.12.5477-5485.2000"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0065-3527(03)61003-1","volume":"61","year":"2003","unstructured":"Halstead, S. B., and J. Jacobson. 2003. Japanese encephalitis. Adv. Virus Res.61:103-138.","journal-title":"Adv. Virus Res."},{"key":"e_1_3_2_24_2","unstructured":"Biosafety in microbiological and biomedical laboratories 2007"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.10.4641-4648.2004"},{"key":"e_1_3_2_26_2","first-page":"75","volume":"267","year":"2002","unstructured":"Holbrook, M. R., and A. D. Barrett. 2002. Molecular epidemiology of Japanese encephalitis virus. Curr. Top. Microbiol. Immunol.267:75-90.","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","volume":"23","year":"2005","unstructured":"Hombach, J., T. Solomon, I. Kurane, J. Jacobson, and D. Wood. 2005. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine23:5205-5211.","journal-title":"Vaccine"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.5.1827-1831.2000"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1128\/CDLI.12.5.566-574.2005","volume":"12","year":"2005","unstructured":"Johnson, A. J., A. J. Noga, O. Kosoy, R. S. Lanciotti, A. A. Johnson, and B. J. Biggerstaff. 2005. Duplex microsphere-based immunoassay for detection of anti-West Nile virus and anti-St. Louis encephalitis virus immunoglobulin M antibodies. Clin. Diagn. Lab. Immunol.12:566-574.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/vbz.2005.5.137","volume":"5","year":"2005","unstructured":"Johnson, B. W., O. Kosoy, D. A. Martin, A. J. Noga, B. J. Russell, A. A. Johnson, and L. R. Petersen. 2005. West Nile virus infection and serologic response among persons previously vaccinated against yellow fever and Japanese encephalitis viruses. Vector Borne Zoonotic Dis.5:137-145.","journal-title":"Vector Borne Zoonotic Dis."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.10.4977-4983.2005"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.1.73-83.1998"},{"key":"e_1_3_2_33_2","first-page":"1486","volume":"2","year":"2007","unstructured":"Lanciotti, R. S., and T. F. Tsai. 2007. Arboviruses, p. 1486-1500. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed., vol. 2. ASM Press, Washington, DC.","journal-title":"Manual of clinical microbiology"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.4.6.503-510.1976"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/sim.1012","volume":"21","year":"2002","unstructured":"Liu, J. P., H. M. Hsueh, E. Hsieh, and J. J. Chen. 2002. Tests for equivalence or non-inferiority for paired binary data. Stat. Med.21:231-245.","journal-title":"Stat. Med."},{"key":"e_1_3_2_36_2","first-page":"544","volume":"9","year":"2002","unstructured":"Martin, D. A., B. J. Biggerstaff, B. Allen, A. J. Johnson, R. S. Lanciotti, and J. T. Roehrig. 2002. Use of immunoglobulin M cross-reactions in differential diagnosis of human flaviviral encephalitis infections in the United States. Clin. Diagn. Lab. Immunol.9:544-549.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.5.1823-1826.2000"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1073\/pnas.91.7.2395","volume":"91","year":"1994","unstructured":"Monath, T. P. 1994. Dengue: the risk to developed and developing countries. Proc. Natl. Acad. Sci. USA91:2395-2400.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_39_2","first-page":"105","volume":"267","year":"2002","unstructured":"Monath, T. P. 2002. Japanese encephalitis vaccines: current vaccines and future prospects. Curr. Top. Microbiol. Immunol.267:105-138.","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0264-410X(01)00457-1","volume":"20","year":"2002","unstructured":"Monath, T. P., K. McCarthy, P. Bedford, C. T. Johnson, R. Nichols, S. Yoksan, R. Marchesani, M. Knauber, K. H. Wells, J. Arroyo, and F. Guirakhoo. 2002. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine20:1004-1018.","journal-title":"Vaccine"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0264-410X(98)00487-3","volume":"17","year":"1999","unstructured":"Monath, T. P., K. Soike, I. Levenbook, Z. X. Zhang, J. Arroyo, S. Delagrave, G. Myers, A. D. Barrett, R. E. Shope, M. Ratterree, T. J. Chambers, and F. Guirakhoo. 1999. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine17:1869-1882.","journal-title":"Vaccine"},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1099\/vir.0.79797-0","volume":"85","year":"2004","unstructured":"Nga, P. T., M. del Carmen Parquet, V. D. Cuong, S. P. Ma, F. Hasebe, S. Inoue, Y. Makino, M. Takagi, V. S. Nam, and K. Morita. 2004. Shift in Japanese encephalitis virus (JEV) genotype circulating in northern Vietnam: implications for frequent introductions of JEV from Southeast Asia to East Asia. J. Gen. Virol.85:1625-1631.","journal-title":"J. Gen. Virol."},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jviromet.2006.09.009","volume":"139","year":"2007","unstructured":"Niedrig, M., K. Sonnenberg, K. Steinhagen, and J. T. Paweska. 2007. Comparison of ELISA and immunoassays for measurement of IgG and IgM antibody to West Nile virus in human sera against virus neutralisation. J. Virol. Methods139:103-105.","journal-title":"J. Virol. Methods"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0065-3527(08)60268-7","volume":"31","year":"1986","unstructured":"Porterfield, J. S. 1986. Antibody-dependent enhancement of viral infectivity. Adv. Virus Res.31:335-355.","journal-title":"Adv. Virus Res."},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.4269\/ajtmh.2004.71.639","volume":"71","year":"2004","unstructured":"Pugachev, K. V., F. Guirakhoo, F. Mitchell, S. W. Ocran, M. Parsons, B. W. Johnson, O. L. Kosoy, R. S. Lanciotti, J. T. Roehrig, D. W. Trent, and T. P. Monath. 2004. Construction of yellow fever\/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool. Am. J. Trop. Med. Hyg.71:639-645.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_2_46_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0065-3527(03)59005-4","volume":"59","year":"2003","unstructured":"Roehrig, J. T. 2003. Antigenic structure of flavivirus proteins. Adv. Virus Res.59:141-175.","journal-title":"Adv. Virus Res."},{"key":"e_1_3_2_47_2","first-page":"356","year":"2000","unstructured":"Roehrig, J. T. 2000. Arboviruses, p. 356-373. In S. Spector, R. Hodinka, and S. Young (ed.), Clinical virology manual, 3rd ed. ASM Press, Washington, DC.","journal-title":"Clinical virology manual"},{"key":"e_1_3_2_48_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/vim.2008.0007","volume":"21","year":"2008","unstructured":"Roehrig, J. T., J. Hombach, and A. D. Barrett. 2008. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol.21:123-132.","journal-title":"Viral Immunol."},{"key":"e_1_3_2_49_2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4049\/jimmunol.99.2.285","volume":"99","year":"1967","unstructured":"Russell, P. K., A. Nisalak, P. Sukhavachana, and S. Vivona. 1967. A plaque reduction test for dengue virus neutralizing antibodies. J. Immunol.99:285-290.","journal-title":"J. Immunol."},{"key":"e_1_3_2_50_2","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1056\/NEJMp058263","volume":"355","year":"2006","unstructured":"Solomon, T. 2006. Control of Japanese encephalitis\u2014within our grasp? N. Engl. J. Med.355:869-871.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_51_2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.68.4.405","volume":"68","year":"2000","unstructured":"Solomon, T., N. M. Dung, R. Kneen, M. Gainsborough, D. W. Vaughn, and V. T. Khanh. 2000. Japanese encephalitis. J. Neurol. Neurosurg. Psychiatry68:405-415.","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.5.3091-3098.2003"},{"key":"e_1_3_2_53_2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1086\/517358","volume":"177","year":"1998","unstructured":"Tsai, T. F., Y. X. Yu, L. L. Jia, R. Putvatana, R. Zhang, S. Wang, and S. B. Halstead. 1998. Immunogenicity of live attenuated SA14-14-2 Japanese encephalitis vaccine\u2014a comparison of 1- and 3-month immunization schedules. J. Infect. Dis.177:221-223.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_54_2","unstructured":"Guidelines for plaque reduction neutralizing testing of human antibodies to dengue viruses. 2007"},{"key":"e_1_3_2_55_2","unstructured":"WHO-recommended standards for surveillance of selected vaccine-preventable diseases. 2003"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.9.4217-4223.2003"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.1.65-72.2004"},{"key":"e_1_3_2_58_2","first-page":"77","volume":"1","year":"1981","unstructured":"Yu, Y.-X., P. F. Wu, J. Ao, L. H. Liu, and H. M. Lim. 1981. Selection of a better immunogenic and highly attenuated live vaccine virus strain of JE. I. Some biological characteristics of SA14-14-2 mutant. Chin. J. Microbiol. Immunol.1:77-84.","journal-title":"Chin. J. Microbiol. Immunol."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00095-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00095-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T18:23:07Z","timestamp":1710354187000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00095-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1128\/CVI.00095-09"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00095-09","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"2009-02-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-05-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}